Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenbendazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albendazole SCHEMBL7969988 | 0.92 | LMNA (0.83) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Albendazole SCHEMBL44682 | 0.92 | LMNA (0.83) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Albendazole SCHEMBL29409236 | 0.92 | LMNA (0.83) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Albendazole SCHEMBL15553526 | 0.91 | LMNA (0.74) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Fenbendazole SCHEMBL28193035 | 0.91 | LMNA (0.76) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Albendazole SCHEMBL28958723 | 0.91 | LMNA (0.81) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Albendazole SCHEMBL28582887 | 0.91 | LMNA (0.81) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Fenbendazole SCHEMBL31547342 | 0.91 | LMNA (0.82) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Fenbendazole SCHEMBL166352 | 0.91 | LMNA (0.82) | LMNACYP1A2MEN1KMT2AMAPK1 | |
| Fenbendazole SCHEMBL31547327 | 0.91 | LMNA (0.82) | LMNACYP1A2MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801855-B2 | Nanocrystalline solid dispersion compositions and process of preparation thereof | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (NIPER) (IN) | 2017-10-31 | — | — | US | claimed |
| US-11832872-B2 | Resonating probe with optional sensor, emitter, and/or injection capability | GETMAN ANYA L (US) | 2023-12-05 | — | — | US | disclosed |
| US-20200305967-A1 | RESONATING PROBE WITH OPTIONAL SENSOR, EMITTER, AND/OR INJECTION CAPABILITY | GETMAN ANYA L (US) | 2020-10-01 | — | — | US | disclosed |
| US-20080153906-A1 | Water-Soluble Phenicol Prodrugs in a Lipophilic Vehicle System | INTERVET INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153906-A1 | Water-Soluble Phenicol Prodrugs in a Lipophilic Vehicle System | BPHL, CYP4B1, CYP4A22 | LMNA 614/4885CYP1A2 10/4885MEN1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.